Tumorigenesis and the angiogenic switch - PubMed (original) (raw)

Review

doi: 10.1038/nrc1093.

Affiliations

• PMID: 12778130
• DOI: 10.1038/nrc1093

Review

Tumorigenesis and the angiogenic switch

Gabriele Bergers et al. Nat Rev Cancer. 2003 Jun.

Abstract

It has become evident that we cannot understand tumour growth without considering components of the stromal microenvironment, such as the vasculature. At the same time, the tumour phenotype determines the nature of the tumour vasculature. Much research is now devoted to determining the impact of angiogenesis on tumour development and progression, and the reciprocal influences of tumour products on the microvasculature. A more detailed understanding of the complex parameters that govern the interactions between the tumour and vascular compartments will help to improve anti-angiogenic strategies-- not only for cancer treatment, but also for preventing recurrence.

PubMed Disclaimer

Similar articles

• Angiopoietins in malignancy.
  Bach F, Uddin FJ, Burke D. Bach F, et al. Eur J Surg Oncol. 2007 Feb;33(1):7-15. doi: 10.1016/j.ejso.2006.07.015. Epub 2006 Sep 7. Eur J Surg Oncol. 2007. PMID: 16962282 Review.
• Role of the microenvironment in tumor growth and in refractoriness/resistance to anti-angiogenic therapies.
  Shojaei F, Ferrara N. Shojaei F, et al. Drug Resist Updat. 2008 Dec;11(6):219-30. doi: 10.1016/j.drup.2008.09.001. Epub 2008 Oct 23. Drug Resist Updat. 2008. PMID: 18948057 Review.
• Mast cell contribution to angiogenesis related to tumour progression.
  Ribatti D, Crivellato E, Roccaro AM, Ria R, Vacca A. Ribatti D, et al. Clin Exp Allergy. 2004 Nov;34(11):1660-4. doi: 10.1111/j.1365-2222.2004.02104.x. Clin Exp Allergy. 2004. PMID: 15544587 Review.
• Ischemic vascular disease and solid cancers: opposing ends of the angiogenic spectrum?
  Balasubramanian SP, Reed MW. Balasubramanian SP, et al. Med Hypotheses. 2006;67(6):1317-9. doi: 10.1016/j.mehy.2006.04.066. Epub 2006 Jul 7. Med Hypotheses. 2006. PMID: 16828237
• Two-dimensional models of tumour angiogenesis and anti-angiogenesis strategies.
  Orme ME, Chaplain MA. Orme ME, et al. IMA J Math Appl Med Biol. 1997 Sep;14(3):189-205. IMA J Math Appl Med Biol. 1997. PMID: 9306674

Cited by

• Predictive value of serum HIF-1α/HIF-2α and YKL-40 levels for vascular invasion and prognosis of follicular thyroid cancer.
  Li J, Yu K, Chen D, Luo G, Jia J. Li J, et al. Clinics (Sao Paulo). 2024 Sep 14;79:100486. doi: 10.1016/j.clinsp.2024.100486. eCollection 2024. Clinics (Sao Paulo). 2024. PMID: 39277981 Free PMC article.
• Targeted anti-angiogenesis therapy for advanced osteosarcoma.
  Zhang Q, Xia Y, Wang L, Wang Y, Bao Y, Zhao GS. Zhang Q, et al. Front Oncol. 2024 Aug 26;14:1413213. doi: 10.3389/fonc.2024.1413213. eCollection 2024. Front Oncol. 2024. PMID: 39252946 Free PMC article. Review.
• Chinese Herbal Compound Xiaoliu Pingyi Recipe Inhibits the Growth of Lung Adenocarcinoma by Regulating the Tumor Vascular Microenvironment.
  Yang FR, Li HL, Hu XW, Fu R, Li XR, Li HJ. Yang FR, et al. Integr Cancer Ther. 2024 Jan-Dec;23:15347354241273962. doi: 10.1177/15347354241273962. Integr Cancer Ther. 2024. PMID: 39223822 Free PMC article.
• Cancer associated fibroblasts and metabolic reprogramming: unraveling the intricate crosstalk in tumor evolution.
  Zhang F, Ma Y, Li D, Wei J, Chen K, Zhang E, Liu G, Chu X, Liu X, Liu W, Tian X, Yang Y. Zhang F, et al. J Hematol Oncol. 2024 Sep 2;17(1):80. doi: 10.1186/s13045-024-01600-2. J Hematol Oncol. 2024. PMID: 39223656 Free PMC article. Review.
• Targeting the tumour vasculature: from vessel destruction to promotion.
  Guelfi S, Hodivala-Dilke K, Bergers G. Guelfi S, et al. Nat Rev Cancer. 2024 Oct;24(10):655-675. doi: 10.1038/s41568-024-00736-0. Epub 2024 Aug 29. Nat Rev Cancer. 2024. PMID: 39210063 Review.

Publication types

MeSH terms

LinkOut - more resources

• Full Text Sources

  • Nature Publishing Group

• Other Literature Sources

  • The Lens - Patent Citations

• Molecular Biology Databases

  • Mouse Genome Informatics (MGI)